User login
Key clinical point: Mucormycosis cases surged after the appearance of COVID-19, but adjunct surgery in COVID-19 patients with mucormycosis improved clinical outcomes.
Major finding: The mortality rate among 99 COVID-19 patients with mucormycosis was 34%. However, 81% of the patients underwent adjunct surgery, which significantly improved outcomes (P < 0.001).
Study details: The data come from 30 case series and case reports totaling 99 patients with COVID-19-associated mucormycosis (CAM). Glucocorticoids, a known risk factor for CAM, were used in 85% of the patients, and the average time from COVID-19 diagnosis to CAM diagnosis was 15 days.
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Source: Pal R et al. Mycoses. 2021 Jun 16. doi: 10.1111/myc.13338.
Key clinical point: Mucormycosis cases surged after the appearance of COVID-19, but adjunct surgery in COVID-19 patients with mucormycosis improved clinical outcomes.
Major finding: The mortality rate among 99 COVID-19 patients with mucormycosis was 34%. However, 81% of the patients underwent adjunct surgery, which significantly improved outcomes (P < 0.001).
Study details: The data come from 30 case series and case reports totaling 99 patients with COVID-19-associated mucormycosis (CAM). Glucocorticoids, a known risk factor for CAM, were used in 85% of the patients, and the average time from COVID-19 diagnosis to CAM diagnosis was 15 days.
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Source: Pal R et al. Mycoses. 2021 Jun 16. doi: 10.1111/myc.13338.
Key clinical point: Mucormycosis cases surged after the appearance of COVID-19, but adjunct surgery in COVID-19 patients with mucormycosis improved clinical outcomes.
Major finding: The mortality rate among 99 COVID-19 patients with mucormycosis was 34%. However, 81% of the patients underwent adjunct surgery, which significantly improved outcomes (P < 0.001).
Study details: The data come from 30 case series and case reports totaling 99 patients with COVID-19-associated mucormycosis (CAM). Glucocorticoids, a known risk factor for CAM, were used in 85% of the patients, and the average time from COVID-19 diagnosis to CAM diagnosis was 15 days.
Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.
Source: Pal R et al. Mycoses. 2021 Jun 16. doi: 10.1111/myc.13338.